Lessons learned after 20 years of real-world experience with natalizumab

Avila R., Adams B., Stevenson J., et al. PML incidence rates in US patients treated with natalizumab: Update from the TOUCH®program. Presented at: Americas Committee For Treatment and Research in Multiple Sclerosis Forum; 2022; West Palm Beach, FL, USA. Biogen, 2023. Tysabri Prescribing Information. https://www.tysabri.com/content/dam/commercial/tysabri/pat/en_us/pdf/tysabri_prescribing_information.pdf. Bloomgren, 2012, Risk of natalizumab-associated progressive multifocal leukoencephalopathy, N. Engl. J. Med., 366, 1870, 10.1056/NEJMoa1107829 Bomprezzi, 2014, Extended interval dosing of natalizumab: a two-center, 7-year experience, Ther. Adv. Neurol. Disord., 7, 227, 10.1177/1756285614540224 Campagnolo, 2016, Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV(R) DxSelect antibody assay, J. Neurovirol., 22, 880, 10.1007/s13365-016-0482-z Chisari, 2020, Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis, J. Neurol. Neurosurg. Psychiatry, 91, 1297, 10.1136/jnnp-2020-323472 De Mercanti, 2021, MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study, J. Neurol. Sci., 424, 10.1016/j.jns.2021.117385 Foley, 2022, Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial, Lancet Neurol., 21, 608, 10.1016/S1474-4422(22)00143-0 Ho, 2017, Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies, Lancet Neurol., 16, 925, 10.1016/S1474-4422(17)30282-X Kågström, 2021, Reduction of the risk of PML in natalizumab treated MS patients in Sweden: an effect of improved PML risk surveillance, Mult. Scler. Relat. Disord., 50, 10.1016/j.msard.2021.102842 McGuigan, 2016, Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group, J. Neurol. Neurosurg. Psychiatry, 87, 117 Plavina, 2014, Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy, Ann. Neurol., 10.1002/ana.24286 Riancho, 2021, Does extended interval dosing natalizumab preserve effectiveness in multiple sclerosis? A 7 year-retrospective observational study, Front. Immunol., 12, 10.3389/fimmu.2021.614715 Ryerson, 2019, Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing, Neurology, 93, e1452, 10.1212/WNL.0000000000008243 Ryerson, 2022, No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: real-world evidence from MS PATHS, Mult. Scler. Relat. Disord., 58, 10.1016/j.msard.2021.103480 van Kempen, 2020, Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial, Neurology, 95, e745, 10.1212/WNL.0000000000009995 Vukusic, 2020, Progressive multifocal leukoencephalopathy incidence and risk stratification among natalizumab users in France, JAMA Neurol., 77, 94, 10.1001/jamaneurol.2019.2670 Yamout, 2018, Efficacy and safety of natalizumab extended interval dosing, Mult. Scler. Relat. Disord., 24, 113, 10.1016/j.msard.2018.06.015 Zhovtis Ryerson, 2016, Extended interval dosing of natalizumab in multiple sclerosis, J. Neurol. Neurosurg. Psychiatry, 87, 885, 10.1136/jnnp-2015-312940